BioCardia Inc
Research BioCardia Inc (BCDA) on Bullrun: market cap USD 16.93M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerBCDA
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 16.93M
- Financial periodQ1 2026
- RevenueUSD 0
- Net income-USD 2.26M
- Free cash flow-USD 7.49M
Valuation Snapshot
latest market cap is USD 16.93M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 0 | -USD 8.23M | -USD 7.44M | n/a | -2.46 | USD 2.50M | USD 528.00K | USD 895.00K |
| FY2024 | USD 58.00K | -USD 7.95M | -USD 7.89M | n/a | -5.74 | USD 2.37M | USD 951.00K | USD 837.00K |
| FY2023 | USD 477.00K | -USD 11.57M | -USD 9.99M | n/a | -7.41 | USD 1.10M | USD 1.32M | -USD 1.60M |
| FY2022 | USD 1.35M | -USD 11.91M | -USD 10.63M | n/a | n/a | USD 7.36M | USD 1.77M | USD 4.89M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 16.93M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 13.44M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 10.03M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 15.59M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 41.90M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 32.73M | n/a | n/a | n/a |
About BioCardia Inc
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is BioCardia Inc's market cap?
BioCardia Inc's market capitalization is USD 16.93M.
What does BioCardia Inc do?
BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.